Trials / Completed
CompletedNCT01697488
An Observational Study of Avastin (Bevacizumab) in Combination With Carboplatin/Paclitaxel in First Line in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (OTILIA)
Non-interventional Surveillance Study (NIS) on First-line (FL) Bevacizumab (Avastin) in Combination With Carboplatin/Paclitaxel in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,090 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This observational study will evaluate the safety, efficacy, quality of life and predictive/selection factors for Avastin (bevacizumab) in combination with carboplatin/paclitaxel in first line in patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in clinical practice. Data of eligible patients will be collected during up to 15 months of treatment and 12 months of follow-up. A second recruitment phase has been opened to focus on patients \>/= 70 years.
Conditions
Timeline
- Start date
- 2012-02-02
- Primary completion
- 2019-09-27
- Completion
- 2019-09-27
- First posted
- 2012-10-02
- Last updated
- 2019-10-08
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01697488. Inclusion in this directory is not an endorsement.